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INTRODUCTION
Metabolic syndrome comprises a spectrum of medical 
disorders associated with an increased risk of developing 
type 2 diabetes mellitus and cardiovascular disease (CVD).(1) 
Metabolic syndrome affects a great number of people and it is 
estimated that approximately 20%–25% of the world’s adult 
population suffers from it.(2) The reported prevalence of metabolic 
syndrome in Asians is lower (5%–16%).(3-5) However, the 
incidence of metabolic syndrome in Malaysia is much higher 
compared to other Asian countries.(6) According to the World 
Health Organization, National Cholesterol Education Program 
(NCEP) ATP III, International Diabetes Federation and 
Harmonized metabolic syndrome definitions, the overall crude 
prevalences of metabolic syndrome in Malaysia are 32.1%, 
34.3%, 37.1% and 42.5%, respectively.(6) Metabolic syndrome 
not only entails serious health complications but also places 
individuals at a greater risk of other serious medical conditions 
such as CVD.(7)
 The pathophysiology of metabolic syndrome is extremely 
complex and is not fully understood. Insulin resistance and 
central obesity are considered to be important underlying causes 
of metabolic syndrome.(8,9) Some individuals may be at greater 
risk of developing metabolic syndrome due to medications that 
cause weight gain or changes in blood pressure, cholesterol and 
blood sugar levels.(10) Atypical antipsychotics have been reported 
to be associated with the increased risks of hyperglycaemia and 
impaired glucose levels, and consequently, an increased risk of 
developing metabolic syndrome.(11) It has also been shown that 
psychiatric disorders, including schizophrenia, are associated 
with an elevated risk of developing diabetes mellitus regardless 
of antipsychotic use.(12) Patients with schizophrenia are at a greater 
risk for metabolic dysfunctions than other individuals due to a 
number of reasons, including an inactive lifestyle, poor dietary 
choices as well as the side effects of antipsychotic medications.(13)
 Cohn et al used the NCEP ATP III criteria to assess metabolic 
syndrome in 240 patients with schizophrenia or schizoaffective 
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INTRODUCTION This study aimed to determine the prevalence of metabolic syndrome and risk of coronary heart  
disease (CHD) in patients with schizophrenia receiving antipsychotics in Malaysia.
MeThODs This cross-sectional study, conducted at multiple centres, involved 270 patients who fulfilled the Diagnostic 
and Statistical Manual of Mental Disorders (DSM)-IV-TR diagnostic criteria for schizophrenia, were on antipsychotic 
medications for at least one year, and were screened for metabolic syndrome. Patients receiving mood stabilisers 
were excluded. Metabolic syndrome was defined according to the National Cholesterol Education Program ATP III  
criteria modified for Asian waist circumference. Risk for cardiovascular disease was assessed by using Framingham 
function (all ten-year CHD events).
ResUlTs The prevalence of metabolic syndrome was 46.7% (126/270). Among all the antipsychotics used, atypical 
antipsychotics (monotherapy) were most commonly used in both the metabolic and non-metabolic syndrome groups 
(50.8% vs. 58.3%). The ten-year risk for CHD was significantly higher in patients with metabolic syndrome. The proportion 
of patients with high/very high risk for CHD (Framingham ≥ 10%) was greater in patients with metabolic syndrome than 
in those with non-metabolic syndrome (31.5% vs. 11.0%, odds ratio 3.9, 95% confidence interval 2.0–7.6; p < 0.001). 
The mean body mass index was higher in patients with metabolic syndrome than in those without (29.4 ± 5.1 kg/m2 vs.  
25.0 ± 5.6 kg/m2; p < 0.001).
CONClUsION Patients with schizophrenia receiving antipsychotics in Malaysia have a very high incidence of  
metabolic syndrome and increased cardiovascular risk. Urgent interventions are needed to combat these problems in 
patients.
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disorder, and reported a gender-based prevalence of 42.6% in 
men and 48.5% in women.(14) They also reported comparable 
incidence among patients under (43.8%) and over (45.8%) 45 
years of age. Using the same definition of metabolic syndrome, 
studies have described the prevalence of metabolic syndrome in 
inpatients with schizophrenia to range between 27%–29%(15,16) 
and in outpatients to be between 25%–35%.(17,18)
 In Southeast Asia, especially in Malaysia, there is a 
paucity of data on the prevalence of metabolic syndrome and 
cardiovascular risk among patients with schizophrenia. A local 
study on 51 patients with primary psychotic and mood disorders 
by Rahman et al found the prevalence of metabolic syndrome 
to be 37.2% in these patients.(19) In the present study, we aimed 
to determine the prevalence of metabolic syndrome in patients 
with schizophrenia receiving antipsychotics in Malaysia as well as 
the risk of coronary heart disease (CHD) in these patients.
MeThODs
The study was conducted at four mental institutions (Hospital 
Bahagia Ulu Kinta, Perak; Hospital Permai Johor Bahru, Johor; 
Hospital Sentosa Kuching, Sarawak; Hospital Mesra Kota 
Kinabalu, Sabah), two army hospitals (Terendak Army Hospital, 
Melaka; Navy Hospital Lumut, Perak) and two general hospitals 
(University Malaya Medical Centre [UMMC], Kuala Lumpur; 
Hospital Sg Petani, Kedah) from June 2008 to September 2011.
 The study population comprised patients with schizophrenia 
between 18–65 years of age who fulfilled the Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV-TR diagnostic 
criteria for schizophrenia. The patients must have received 
antipsychotic treatment for at least one year. Patients receiving 
mood stabilisers were excluded from the study, as it could 
have confounded the parameters of weight gain and metabolic 
syndrome.(20,21) One patient on lithium and three others on 
sodium valproate were excluded. Out of 527 patients who were 
screened during the study period, 485 patients fulfilled the DSM-
IV-TR criteria for schizophrenia. 325 patients with schizophrenia 
agreed to be interviewed and underwent part assessment for 
metabolic syndrome parameters. However, only 270 patients gave 
final consent for fasting blood investigations and full metabolic 
syndrome profile. All participants were outpatients. There was 
no difference between the group of patients who consented to 
participation and those who did not, in terms of sociodemographics 
or diagnosis.
 The prevalence of metabolic syndrome was estimated using 
the NCEP criteria (the 2001 Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults) modified 
for the Asian waist circumference(22) based on the presence 
of three or more of the following components – abdominal 
obesity (waist circumference: men ≥ 90 cm; women ≥ 80 cm), 
hypertriglyceridaemia (fasting triglyceride concentration 
> 150 mg /dL),  dyslipidaemia (fas t ing high-densit y 
lipoprotein [HDL] cholesterol: men < 40 mg/dL; women 
< 50 mg/dL), hypertension (systolic/diastolic blood pressure, 
> 130/85 mmHg) and hyperglycaemia (fasting glucose 
concentration > 100 mg/dL).
 Waist circumference was measured at the midpoint between 
the lower rib margin (12th rib) and the iliac crest. Participants were 
asked to stand with feet together and arms in a relaxed position 
at either side during measurement. A tape was then held in a 
horizontal position and wrapped around the waist, loose enough 
for the recorder to place one finger between the tape and the 
participant’s body. Patients were asked to breathe normally and 
measurements were taken to the nearest 0.1 cm at the end of a 
normal exhalation. It was ascertained that participants did not 
contract the abdominal muscles during measurements.
 Blood pressure was measured using a  digi t al 
sphygmomanometer (Omron Digital Automatic Blood Pressure 
Monitor Model HEM-907, Omron Healthcare Co Ltd, Kyoto, 
Japan) on both the right and left arms following a rest of five 
minutes in a seated position, with the arm supported at heart 
level. Each arm was measured twice and measurements from the 
arm with the highest readings were used to calculate the average 
systolic and diastolic blood pressures. To minimise variability in 
anthropometric measurements between recorders and study 
centres, the main investigators from each institution attended 
an investigators meeting, held prior to the start of the study. 
Procedures were standardised and appropriate training was 
provided as part of the meeting. Training for the remaining 
members of the research team was subsequently carried out by the 
main investigators at their respective institutions. All anthropometric 
measurements for the duration of the study were carried out by 
these trained team members.
 The Framingham(23) function was used to estimate the overall 
risk of fatal or nonfatal CHD (including any type of angina, 
myocardial infarction, other types of coronary ischaemia, 
congestive heart failure, intermittent claudication or peripheral 
arterial ischaemia) over ten years. The Framingham function is 
a mathematical probability model obtained using multivariate 
analysis from follow-up studies of individuals in the general 
population, in which the incidence of a fatal or nonfatal CHD 
event is related to the individual risk factors of each participant. 
Risk of CHD was calculated from the values meant for age, gender, 
total cholesterol, HDL cholesterol, blood pressure, diabetes 
mellitus status and smoking status. Patients were classified 
according to the probability of presenting a high/very high 
risk for fatal or nonfatal CHD (Framingham ≥ 10%) within 
ten years.
 Sociodemographic and clinical data were recorded for all 
participants in addition to detailed information on lifestyle, 
smoking and occupational status. Patients were classified into 
two groups – metabolic syndrome and non-metabolic syndrome 
– according to the criteria mentioned above. The mean, standard 
deviation, median and interquartile range were calculated for 
continuous variables, and the frequency and percentage of 
patients were used to estimate the prevalence of cardiovascular 
risk factors and the components of metabolic syndrome. Individual 
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prevalence of cardiovascular risk factors and the prevalence 
of metabolic syndrome components were estimated by 
calculating the corresponding 95% confidence intervals. 
Framingham risk scores in the metabolic syndrome and non-
metabolic syndrome patient groups were compared using 
parametric (Student’s t-test) or nonparametric (Mann-Whitney U 
test) tests, according to the distribution of variables. The risk score 
of patients were further classified as low (Framingham < 10%) 
or high/very high (Framingham ≥ 10%) ten-year risk of CHD. 
The categorical risk scores were compared using chi-square test. 
A p-value < 0.05 was considered statistically significant.
 The least squares mean of Framingham risk scores were also 
compared according to patient age groups with and without 
metabolic syndrome. The multiple comparisons were analysed 
using two-way interaction in three-way analysis of variance 
(ANOVA), with Bonferroni correction and adjustment for 
gender. Statistical analysis was performed using the Statistical 
Package for the Social Sciences for Windows version 16.0 (SPSS 
Inc, Chicago, IL, USA). Ethics approval for the study was obtained 
in advance from the Medical Research and Ethics Committee, 
Ministry of Health Malaysia, and University Malaya Medical 
Centre Ethics Committee.
ResUlTs
The prevalence of metabolic syndrome in patients with 
schizophrenia was 46.7% (126/270). The mean body mass 
index (BMI) showed a statistically significant difference between 
patients with metabolic syndrome and non-metabolic syndrome. 
The mean BMI for metabolic syndrome patients was higher than 
that for the non-metabolic syndrome group (29.4 ± 5.1 kg/m2 vs. 
25.0 ± 5.6 kg/m2). A majority of patients with metabolic syndrome 
were overweight (39.7% vs. 24.3%) and obese (40.5% vs. 17.4%) 
compared to those in the non-metabolic group (Table I).
 Table II presents the antipsychotics and other concomitant 
medications that were given to patients during the study. Among 
all antipsychotics used, atypical antipsychotics (monotherapy) 
were used the most in both metabolic syndrome and 
non-metabolic syndrome group patients (50.8% vs. 58.3%), 
followed by typical antipsychotics (monotherapy), also in both 
patient groups (21.4% vs. 20.8%). Among patients receiving 
typical antipsychotics (monotherapy) treatment, chlorpromazine 
(33.3%) was given the most to patients in the metabolic syndrome 
group, followed by sulpiride and perphenazine (18.5% each). 
Among patients receiving atypical antipsychotics (monotherapy) 
treatment, olanzapine (42.2%) was given most frequently to 
patients in the metabolic syndrome group followed by risperidone 
(32.8%). None of the patients on amisulpride had metabolic 
syndrome (Table II).
 Table III shows statistically significant differences for all 
metabolic syndrome components, except low-density lipoprotein 
(LDL) cholesterol, between patients in the metabolic syndrome 
and non-metabolic syndrome groups. The median values of 
fasting blood glucose, triglycerides and glycated haemoglobin 
were also significantly different between patients in the 
metabolic syndrome and non-metabolic syndrome groups (Mann-
Whitney U test). Among all the metabolic syndrome components, 
abnormal waist circumference was the commonest among 
patients in the metabolic syndrome and non-metabolic syndrome 
Table I. Characteristics of patients with schizophrenia (n = 270).




disease (n = 144)
Mean age ± sD (yrs) 40.5 ± 11.3 39.5 ± 11.8 0.472§
Age group (yrs)
< 20† 2 (1.6) 2 (1.4) 0.500
20–29 18 (14.3) 34 (23.6)
30–39 44 (34.9) 40 (27.8)
40–49 29 (23.0) 32 (22.2)
50–59 26 (20.6) 27 (18.8)
≥ 60 7 (5.6) 9 (6.2)
Mean BMI ± sD (kg/m2) 29.4 ± 5.1 25.0 ± 5.6 < 0.001§,¶
BMI group (kg/m2)
Underweight‡ (< 18.5) 0 (0) 14 (9.7)
Normal weight† (18.5–24.9) 25 (19.8) 70 (48.6) < 0.001¶
Overweight (25–29.9) 50 (39.7) 35 (24.3)
Obese (≥ 30) 51 (40.5) 25 (17.4)
Gender
Male† 74 (58.7) 100 (69.4) 0.747
Female 52 (41.3) 44 (30.6)
Occupation
Employed† 33 (26.1) 55 (38.2) 0.003¶
Unemployed 83 (65.9) 67 (46.5)
Housewife 6 (4.8) 5 (3.5)
Not specified 4 (3.2) 17 (11.8)
*Chi-square test. †Reference group.‡Patients who were underweight (BMI < 18.5 kg/m2) were excluded, and only the data of those categorised as normal, 
overweight and obese were used for chi-square analysis. §t-test. ¶p < 0.05 was statistically significant.
BMI: body mass index; SD: standard deviation
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groups (98.4% vs. 50.7%), followed by HDL cholesterol (72.6% 
vs. 30.9%); fasting blood glucose was the least common in the 
two patient groups (51.6% vs. 6.2%) (Table III).
 31.5% of patients in the metabolic syndrome group had a high/
very high ten-year risk of CHD, while the corresponding figure 
for patients in the non-metabolic syndrome group was 11.0%. 
The difference in incidence of high/very high ten-year risk of CHD 
was statistically significant between the two groups (p < 0.001). 
Also significant was the difference in the median Framingham 
risk scores of the two patient groups (p < 0.001). The mean 
Framingham risk score for the metabolic syndrome group was 
7.6 (i.e, 8/100 people with this level of risk were likely to have a 
heart attack in the next ten years) while that for the non-metabolic 
syndrome group was 5.0 (i.e. 5/100 people with this level of risk 
might have a heart attack in the next ten years) (Table IV).
 There was a greater increase in the mean scores of CHD risk 
for patients of all age groups in the metabolic syndrome group 
compared to those in the non-metabolic syndrome group. There 
was a significant difference in the mean score of CHD risk for 
patients of all age groups except those over 60 years of age (Fig. 1).
DIsCUssION
Our study was aimed at estimating the prevalence of metabolic 
syndrome in patients with schizophrenia in the local population 
who were being treated with antipsychotic medications for at 
least one year. Our results showed that 46.7% of patients fulfilled 
the criteria for metabolic syndrome, as defined by NCEP ATP 
III guidelines. This incidence is considerably higher than the 
reported prevalence of metabolic syndrome in both the general 
Malaysian (34.3%)(6) and Asian populations (5%–16%).(3-5)
 The higher prevalence of metabolic syndrome in patients with 
schizophrenia has frequently been reported.(14,24) For instance, 
a study by Cohn et al(14) found that the prevalence of metabolic 
syndrome in men and women with schizophrenia was 42.6% 
and 48.5%, respectively, using the same criteria. Similarly, a 
Japanese study by Sugawara et al reported a 48.1% incidence of 
metabolic syndrome in outpatients with schizophrenia.(24)
 The reasons for a higher rate of metabolic syndrome being 
associated with schizophrenia are many. Certain lifestyles (such 
as sedentary habits and intake of high-fat and high-carbohydrate 
diets) that are frequently seen in people with severe mental illness 
are associated with metabolic syndrome.(25,26) Schizophrenia may 
predispose individuals to physiological changes that increase the 
risk of metabolic syndrome. For instance, abnormalities in glucose 
regulation along with a pattern of insulin resistance have been 
described in schizophrenic patients even prior to the development 
of illness or the use of antipsychotic agents.(27,28) Some antipsychotics 
are associated with a high occurrence of the development of 
metabolic syndrome. These medications may cause weight gain 
or changes in blood pressure, cholesterol and blood sugar levels.(10) 
Table II. Treatment with antipsychotics and other medications in patients with schizophrenia.




disease (n = 144)
Current antipsychotics
Atypical antipsychotics (monotherapy)† 64 (50.8) 84 (58.3) 0.339
Typical antipsychotics (monotherapy) 27 (21.4) 30 (20.8)
Combination of typical and atypical antipsychotics 15 (11.9) 11 (7.7)
Combination of typical antipsychotics 14 (11.1) 9 (6.2)
Combination of atypical antipsychotics 6 (4.8) 10 (7.0)
Typical antipsychotics (monotherapy)
Chlorpromazine 9 (33.3) 10 (33.3)
Sulpiride 5 (18.5) 6 (20.0)
Perphenazine 5 (18.5) 5 (16.7)
Haloperidol† 3 (11.2) 5 (16.7) 0.960
Stelazine 2 (7.4) 1 (3.3)
Intramuscular fluanxol 2 (7.4) 1 (3.3)
Intramuscular modecate 1 (3.7) 2 (6.7)
Atypical antipsychotics (monotherapy)
Olanzapine† 27 (42.2) 26 (31.0) 0.390
Risperidone 21 (32.8) 29 (34.5)
Paliperidone 11 (17.2) 16 (19.0)
Clozapine 2 (3.1) 1 (1.2)
Quetiapine 1 (1.6) 2 (2.4)
Aripiprazole 2 (3.1) 6 (7.1)
Amisulpride 0 (0) 4 (4.8)
Concomitant medication
Anticholinergics 41 (32.5) 44 (30.6) 0.726
Benzodiazepine 25 (19.8) 22 (15.3) 0.324
Antidepressants 16 (12.7) 19 (13.2) 0.904
Other medication
Antidiabetic medication 8 (6.3) 5 (3.5) 0.271
Blood pressure-lowering medication 6 (4.8) 6 (4.2) 0.813
Lipid-lowering medication 6 (4.8) 10 (6.9) 0.449
*Chi-square test. †Reference group.
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Table III. Metabolic syndrome components according to metabolic syndrome status in patients with schizophrenia.
Component Metabolic disease (n = 126) Non-metabolic disease (n = 144) Total (n = 270) p-value*
No. (%) 95% CI No. (%) 95% CI No. (%) 95% CI
Waist circumference  
(men ≥ 90 cm; 
women ≥ 80 cm)
124 (98.4) 94.4–99.6 73 (50.7) 42.6–58.7 197 (73.0) 67.4–77.9  < 0.001‡
hDlC† (men < 40 mg/dl;  
women < 50 mg/dl)
90  (72.6) 64.1–79.7 42 (30.9) 23.7–39.1 132 (50.8) 44.7–56.8  < 0.001‡
Triglyceride†  
(≥ 150 mg/dl)
84 (67.7) 59.1–75.3 21  (15.4) 10.3–22.5 105 (40.4) 44.7–56.8  < 0.001‡
BP (≥ 130/85 mmhg) 77 (61.1) 52.4–69.2 36 (25.0) 18.6–32.7 113 (41.9) 36.1–47.8  < 0.001‡
Fasting blood glucose 
(≥ 100 mg/dl)
65 (51.6) 42.9–60.1 9 (6.2) 3.3–11.5 74 (27.4) 22.4–33.0  < 0.001‡
laboratory test parameter
Fasting blood glucose (mg/dL)
Mean ± SD 110.5 ± 37.9 103.9–117.2 89.2 ± 21.3 85.7–92.7 99.2 ± 31.9 95.3–103.0
Median (IQR) 100.8 (88.2–113.4) 86.4 (81.0–91.8) 90.0 (82.8–100.8) < 0.001‡,§
Triglycerides (mg/dL)
Mean ± SD 214.1 ± 57.0 185.5–242.6 116.9 ± 57.0 107.2–126.6 163.2 ± 127.9 147.6–178.9
Median (IQR) 171.8 (125.8–245.3) 113.8 (81.5–138.2) 132.9 (97.4–186) < 0.001‡,§
HbA1c (%)
Mean ± SD 6.4 ± 1.7 6.1–6.7 5.5 ± 0.7 5.4–5.6 5.9 ± 1.3 5.8–6.1
Median (IQR) 5.9 (5.6–6.5) 5.4 (5.2–5.8) 5.6 (5.3–6.1) < 0.001‡,§
Mean TC ± SD (mg/dL) 216.1 ± 46.5 207.8–224.3 202.2 ± 41.3 195.2–209.2 208.8 ± 44.3 203.4–214.2 0.011‡,¶
Mean LDLC ± SD (mg/dL) 136.6 ± 40.4 129.1 –144.0 131.1 ± 40.4 124.2–138.0 133.6 ± 40.4 128.6–138.6 0.287¶
HDLC ± SD (mg/dL)
Men 37.9 ± 6.8 36.3–39.5 46.0 ± 13.0 43.3–48.6 42.5 ± 11.5 40.7–44.2 < 0.001‡,¶
Women 44.5 ± 10.7 41.5–47.5 52.8 ± 13.6 48.5–57.1 48.2 ± 12.7 45.5–50.8 0.001‡,¶
Other parameters
Mean waist circumference 
± SD (cm)
Men 102.4 ± 9.8 100.1–104.7 87.5 ± 13.8 84.7–90.2 93.9 ± 13.9 91.9–95.8 < 0.001‡,¶
Women 96.7 ± 10.8 93.7–99.7 88.6 ± 13.7 84.4–92.8 91.7 ± 13.1 89.4–94.0 0.002‡,¶
Mean systolic BP  
± SD (mmHg)
127.0 ± 16.7 124.0–130.0 117.4 ± 17.4 114.5–120.2 121.6 ± 18.2 119.7–123.6 < 0.001‡,¶
Mean diastolic BP 
± SD (mmHg)
83.8 ± 12.7 81.6–86.1 77.1 ± 11.9 75.1–79.1 80.7 ± 13.0 79.3–82.1 < 0.001‡,¶
*Chi-square test. †For triglycerides and HDLC (n = 260). ‡p < 0.05 was statistically significant. §Mann-Whitney U test. ¶t-test.
CI: confidence interval; BP: blood pressure; HbA1c: glycated haemoglobin; IQR: interquartile range; TC: total cholesterol; HDLC: high-density lipoprotein 
cholesterol; LDLC: low-density lipoprotein cholesterol; SD: standard deviation
Table IV. Cardiovascular risk factors and coronary heart disease risk (Framingham) according to metabolic syndrome status in 
patients with schizophrenia.
Variable Metabolic disease 
(n = 126)
Non-metabolic 
disease (n = 144)
Total (n = 270) p-value*
No. (%) 95% CI No. (%) 95% CI No. (%) 95% CI
Cardiovascular risk factors
Age (men ≥ 40 years; women ≥ 45 years) 58 (46.0) 37.6–54.7 64 (44.4) 36.6–52.6 122 (45.2) 39.4–51.2 0.794
Smoker 29 (23.0) 16.5–31.1 47 (32.6) 25.5–40.7 76 (28.1) 23.1–33.8 0.079
Diabetes mellitus (known diagnosis 
or glucose ≥ 126 mg/dL)
26 (20.6) 14.5–28.5 6 (4.2) 1.9–8.8 32 (11.9) 8.5–16.3 < 0.001§
TC† (≥ 200 mg/dL) 80 (64.5) 55.8–72.4 68 (50.0) 41.7–58.3 148 (56.9) 50.9–62.8 0.018§
HDLC† (men < 45 mg/dL; women < 50 mg/dL) 99 (79.8) 71.9–86.0 78 (57.4) 49.0–65.4 177 (68.1) 62.2–73.4 < 0.001§
Mean systolic BP‡ ± SD (men ≥ 140 mmHg;  
women ≥ 130 mmHg) 
28 ± 22.2 15.9–30.2 22 ± 15.3 10.3–22.1 50 ± 18.5 14.3–23.6 0.143
Mean diastolic BP‡ ± SD (men ≥ 90 mmHg;  
women ≥ 80 mmHg) 
42 ± 33.3 25.7–42.0 20 ± 13.9 9.2–20.5 62 ± 23.0 18.4–28.3 < 0.001§
Ten-year risk of ChD (Framingham)
Mean ± SD 7.6 ± 6.4 6.5–8.8 5.0 ± 4.4 4.3–5.8 6.3 ± 5.6 5.6–7.0
Median (IQR) 6.5 (2.5–11.0) 4.0 (1.0–7.0) 4.0 (1.0–9.0) < 0.001§,¶
Patients with high/very high (Framingham ≥ 
10%) ten-year risk of ChD (Framingham)
39 (31.5) 23.9–40.1 15 (11.0) 6.8–17.4 54 (20.8) 16.3–26.1 < 0.001§
*Chi-square test. †For total and HDLC (n = 260). ‡In patients with diabetes mellitus, cardiovascular disease or kidney disease. §p < 0.05 was statistically 
significant. ¶Mann-Whitney U test.
CI: confidence interval; BP: blood pressure; CHD: coronary heart disease; IQR: interquartile range; TC: total cholesterol; HDLC: high-density lipoprotein 
cholesterol; SD: standard deviation
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Studies have shown that atypical antipsychotics are associated 
with an increased risk of hyperglycaemia and impaired glucose 
levels, which consequently increase the risk of metabolic 
syndrome.(11,29,30) Among the patients in our study who had 
metabolic syndrome, 42% of them were on olanzapine, 32.8% 
were on risperidone and 17.2% were on paliperidone.
 We found that the presence of metabolic syndrome in 
schizophrenic patients was associated with CHD risk. A significant 
difference was observed in the cardiovascular risk of patients with 
and without metabolic syndrome. Our results were similar to a 
study in Spain by Bobes et al,(17) which reported high cardiovascular 
risk, as defined by the Framingham score, in patients treated 
with antipsychotic drugs. Correll et al, who studied 367 adult 
patients being treated with atypical antipsychotics, found that 
metabolic syndrome was present in 137 (37.3%) patients and 
it was significantly associated with a ten-year risk of CHD.(31) 
Similarly, Holt el al found that 12% of patients in their 
study with serious mental illness had a > 20% ten-year risk 
of CHD.(32)
 We observed a statistically significant difference in all 
metabolic syndrome components, except LDL cholesterol, between 
patients in the metabolic syndrome and non-metabolic syndrome 
groups. The mean fasting blood sugar level in the metabolic 
syndrome group was clearly impaired (110.5 mg/dL) although it 
was normal in the non-metabolic syndrome group (89.2 mg/dL). 
Men in the non-metabolic syndrome group had normal mean HDL 
cholesterol levels compared to those in the metabolic syndrome 
group. Furthermore, the mean triglyceride level in the metabolic 
syndrome group was nearly double that in the non-metabolic 
syndrome group (214.1 mg/dL vs. 116.9 mg/dL).
 The most common findings in our patients with metabolic 
syndrome were abnormal waist circumference (98.4%), low HDL 
cholesterol (72.6%), raised triglycerides (67.7%) and elevated 
blood pressure (61.1%). Elevated fasting blood glucose was the 
least frequent abnormality. Our results substantiate those by 
Kato et al, who found that the most common metabolic syndrome 
criteria were abnormal waist circumference, dyslipidaemia and 
elevated blood pressure, while the least prevalent metabolic 
component was elevated fasting blood glucose.(33)
 The mean BMI was significantly higher in patients with 
metabolic syndrome (29.4 ± 5.1 kg/m2) in our study than those 
with non-metabolic syndrome (25.0 ± 5.6 kg/m2; p < 0.05). When 
patients were categorised according to weight, a significantly 
higher proportion of overweight (39.7% vs. 24.3%) and obese 
(40.5% vs. 17.4%) patients were seen in the metabolic syndrome 
group than in the non-metabolic syndrome group. Our results 
were similar to that of the CLAMORS study, where general 
obesity and abdominal adiposity were high in outpatients with 
schizophrenia who had metabolic syndrome.(17) The study by 
Bobes et al recorded a two-fold higher rate of obesity in 
outpatients with metabolic syndrome when compared to those 
with non-metabolic syndrome (55.2% vs. 22.7%).(17) The high 
prevalence of obesity and abdominal adiposity among patients 
with schizophrenia who had metabolic syndrome in our study 
was also in agreement with the results of the CATIE study.(34)
 Despite finding higher rates of metabolic syndrome in 
patients with schizophrenia, the present study is not without 
limitations. First, as this was a cross-sectional study, the causal 
pathway of metabolic syndrome in patients with schizophrenia 
could not be inferred from our study even though it was frequent 
in our population. Second, a reference population without 
psychopathology was not to be found although the incidence 
of metabolic syndrome in adult Malaysians was available from a 
nationwide survey.(6)
 In conclusion, we found that the prevalence of metabolic 
syndrome in patients with schizophrenia receiving antipsychotic 
therapy in Malaysia is very high. Our data adds to the mounting 
body of evidence that suggests that patients with schizophrenia 
are at an increased risk of developing metabolic syndrome. 
Our findings highlight the need for urgent formulation of 
comprehensive interventional measures aimed at combating 
problems faced by this patient cohort.
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